What is the main purpose of this VRTX 8-K filing?

The main purpose of this 8-K filing is to officially report that Vertex Pharmaceuticals has issued its press release containing the consolidated financial results for the first quarter ended March 31, 2019. The press release itself is attached as Exhibit 99.1.

Where can I find the detailed Q1 2019 financial results for Vertex Pharmaceuticals?

The detailed Q1 2019 financial results are provided in the press release attached to this 8-K filing as Exhibit 99.1. Investors should refer to this exhibit for comprehensive financial data and commentary.

Does the 8-K filing itself contain the Q1 2019 financial statements?

No, the 8-K filing itself does not contain the detailed financial statements. It acts as a notification that the financial results have been released and are available in the attached press release (Exhibit 99.1).

What is the significance of the disclaimer regarding Section 18 of the Exchange Act?

The disclaimer indicates that the information furnished in Exhibit 99.1 (the press release) is not considered 'filed' under Section 18 of the Securities Exchange Act of 1934. This means it is not subject to the strict liabilities of that section, and it won't be automatically incorporated into future SEC filings unless specifically referenced.

VRTX 8-K: Earnings & Results

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on April 30, 2019, primarily to furnish its press release detailing the company's financial results for the first quarter ended March 31, 2019. The report confirms that Vertex has released its Q1 2019 financial performance, a key event for investors seeking updates on the company's operational and financial health. While the 8-K itself does not contain the detailed financial tables or commentary, it directs readers to the attached press release (Exhibit 99.1) for this crucial information.

Key Highlights

1Vertex Pharmaceuticals filed an 8-K on April 30, 2019, related to its Q1 2019 financial results.
2The primary purpose of the filing is to provide investors with access to the company's first-quarter earnings press release.
3Exhibit 99.1, attached to the 8-K, contains the consolidated financial results for the three months ended March 31, 2019.
4This filing serves as a notification that the Q1 2019 earnings information is publicly available.
5Investors are directed to the press release for detailed financial performance and operational updates for the period.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Apr 30, 2019)

Summary

Key Highlights

Frequently Asked Questions